​

参考文献：

1.中华医学会血液学分会血栓与止血学组. 促血小板生成药物临床应用管理中国专家共识（2023年版）[J]. 中华血液学杂志,2023,44(7):535-542.

2.Vlachodimitropoulou E, Chen YL, Garbowski M, et al. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood. 2017 Oct 26;130(17):1923-1933.

3.刘海龙,王江,林岱宗,等.先导化合物结构优化策略(二)——结构修饰降低潜在毒性[J].药学学报,2014,49(1):1-15.

4.艾曲泊帕乙醇胺片说明书.

5.牛子冉,左玮,邹羽真,等. 艾曲泊帕治疗儿童慢性免疫性血小板减少症的临床效果[J]. 临床药物治疗杂志,2020,18(7):62-66.

6.Winer ES, Safran H, Karaszewska B, et al. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med. 2015 Jan;4(1):16-26.

7.海曲泊帕乙醇胺片说明书.

8.Mei H, Liu X, Li Y, et al. Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study. J Thromb Haemost. 2022 Mar;20(3):716-728.

9.Dong Yan,Jing Yang, Yunfei Gao, et al; Combination of Thrombopoietin Receptor Agonist and Recombinant Human Thrombopoietin for Treating Cancer Therapy Induced Thrombopenia. Blood 2022; 140 (Supplement 1): 8420–8421.

10.陈灿,张其坤,许青. 新型血小板生成素受体激动剂:阿伐曲泊帕[J]. 中国新药与临床杂志,2020,39(11):652-656.

11.马来酸阿伐曲泊帕片说明书.

12.Nomoto M, Pastino G, Rege B, et al. Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects. Clin Pharmacol Drug Dev. 2018 Feb;7(2):188-195.

13.Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev. 2022 May;53:100909.

14.Cui Y, He Y, Hu C, et al. Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial. Front Pharmacol. 2022 Sep 27;13:970978.

15.Gao Y, Liu Q, Shen Y, et al. Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. Platelets. 2022 Oct 3;33(7):1024-1030.

16.Kuter DJ, Allen LF. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. Br J Haematol. 2018 Nov;183(3):466-478.

17.Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018 Nov;183(3):479-490.